• VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
• The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
• VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
• The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”),  and other antibody-based formats.
• VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://ibn.fm/ZcS3w).

The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results provide initial evidence supporting the company’s approach of using dual-targeted mechanisms to activate potent therapeutic payloads only when both components reach the same tumor cell.

Traditional antibody-drug conjugates have transformed parts of cancer treatment by allowing targeted delivery of highly potent therapies. However, a continuing challenge within the field is the unintended exposure of healthy tissue to toxic payloads, which can limit dosing and contribute to adverse effects.

VERAXA’s BiTAC strategy, short for Bi-targeted Tumor-Associated Cytotoxicity, seeks to address this challenge by separating a therapeutic system into two complementary molecules. Individually, these molecules are designed to remain inactive. Therapeutic activity occurs only when both components bind to the intended cancer cell, creating an “AND-gated” approach aimed at improving tumor specificity.

According to the company, this architecture is being applied across two major technology platforms: BiTAC-ADCs and BiTAC-TCEs. The BiTAC-TCE platform was previously presented at the American Association for Cancer Research (“AACR”) Annual Meeting in 2026, where early preclinical data showed selective activity against cells expressing both target markers while reducing effects on cells carrying only one of the targets. Together, the BiTAC-ADC and BiTAC-TCE programs represent VERAXA’s strategy of developing conditionally activated therapies that may offer a broader therapeutic window compared with conventional approaches.

The company entered the public markets in June 2026 following the completion of its business combination with Voyager Acquisition Corp., beginning trading on the NASDAQ Capital Market under the ticker symbol VRXA. The listing provides VERAXA with greater access to capital markets as it advances its pipeline and evaluates future collaboration opportunities.

Beyond its BiTAC programs, VERAXA is developing a broader portfolio of antibody-based therapeutics focused on oncology. The company’s pipeline includes additional mono- and bispecific ADC programs, and other engineered therapeutic formats.

Its most advanced clinical-stage program, VX-A901, is a monoclonal antibody targeting FLT3 for the treatment of acute myeloid leukemia (“AML”). The therapy is designed to stimulate antibody-dependent cellular cytotoxicity, helping immune cells recognize and attack cancer cells. Early Phase I data indicated that the treatment was well tolerated among heavily pre-treated AML patients and showed initial signs of anti-tumor activity. As VERAXA increases its emphasis on solid tumor applications and BiTAC-based modalities, it intends to seek partners for the future development and commercialization of VX-A901.

The company’s research strategy reflects broader trends within the oncology industry, where pharmaceutical developers are increasingly investing in therapies that can improve targeting precision and reduce damage to healthy tissue. ADCs and bispecific antibodies have become important areas of research because they combine the specificity of antibodies with powerful therapeutics. 

Market forecasts indicate substantial growth opportunities in these sectors. According to Grand View Research, the global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is expected to reach about $32.11 billion by 2033, driven by increasing demand for targeted cancer treatments (https://ibn.fm/9L2vF). The market for bispecific antibodies is also projected to expand significantly over the next decade, supported by continued advances in immuno-oncology and precision medicine.

VERAXA traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), a research institution recognized for contributions to molecular biology and biotechnology. The company has built its development platform around proprietary antibody engineering technologies, biorthogonal click chemistry, and tumor-selective activation strategies designed to create more precise cancer therapeutics.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment
• Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability
• Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies

For decades, chemotherapy has carried a basic trade-off. The same drugs that kill cancer cells can also damage healthy tissue, leading to toxicity that can limit dosing, interrupt treatment, and reduce quality of life. Nanomedicine emerged as a strategy to change how a drug distributes throughout the body. By packaging the drug in nanoscale carriers, these formulations keep more drug in circulation long enough to accumulate in tumors, while reducing unnecessary exposure in healthy tissue Early enthusiasm gave way to skepticism as many experimental formulations failed to translate from animal models into clinical products. Now the field appears to be turning a corner, and a growing group of developers is working to define what the next generation of cancer nanomedicine looks like.

A Field Emerging from Skepticism

A 2025 review of clinical cancer nanomedicines published in the Journal of Controlled Release describes a field moving beyond what its authors characterize as a long trough of disillusionment. More than 20 nanomedicine formulations have now reached clinical use.

These products improve the therapeutic index of the drugs they carry, increasing the gap between therapeutic benefit and unwanted toxicity by altering how treatments distribute throughout the body. In doing so, they have measurably improved patient quality of life during treatment.

The review draws a distinction that matters for newer programs. Earlier generations of nanomedicines primarily made existing drugs more tolerable by reducing side effects. The generation now advancing aims to go further, using nanoparticle engineering to enable therapeutic effects that would not be possible with the free drug alone. That shift, from reducing harm to actively improving performance, provides the backdrop for a new wave of oncology development programs.

Where Onco-Innovations Fits

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a Canadian oncology company developing inhibitors of Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. Blocking PNKP is designed to leave cancer cells unable to repair damage caused by radiation and chemotherapy while also exploiting synthetic lethality in tumors carrying specific gene expression deficiencies.

PNKP inhibition represents an emerging class within the broader DNA Damage Response field, a category that generated more than $7 billion in sales in 2025 and continues expanding beyond established PARP inhibitors.

The company’s lead candidate, ONC010, sits squarely within the newer-generation nanomedicine model. It combines A83B4C63, a small-molecule inhibitor of PNKP, with a proprietary polymer nanodelivery system designed to encapsulate and transport the drug. In animal studies, the formulation slowed tumor growth, demonstrated favorable pharmacokinetics and low observed toxicity, and increased sensitivity to radiation and certain chemotherapies.

Why the Delivery Platform Matters

DNA Damage Response inhibitors have a challenging history. Several promising candidates have struggled with off-target toxicity or poor solubility that complicated dosing and distribution. Onco’s nanoparticle approach is designed to address those specific obstacles. A nanodelivery platform is not a cosmetic add-on in this context; it is a key part of the therapeutic design. The nanoparticle formulation helps solubilize and carry a small-molecule inhibitor that would otherwise be difficult to administer. By extending circulation time, concentrating the drug at the tumor site, and limiting exposure to healthy tissue, the delivery system is intended to widen the gap between therapeutic effect and toxicity, the central objective that has driven decades of nanomedicine development.

The company’s approach also aligns with broader trends identified in the clinical nanomedicine literature, where researchers increasingly view advanced delivery systems not simply as tools for reducing side effects, but as platforms capable of improving therapeutic performance.

A Key Manufacturing Partnership

Recent activity points to a growing focus on the scale-up and analytical framework that next-generation nanomedicines require. In June, Onco signed a non-binding letter of intent with Nanosoft Polymers, a North Carolina polymer company, to negotiate support for scaled polymer synthesis process development, analytical characterization, and formulation optimization activities.

Nanosoft is led by Dr. Xiaobing Xiong, who trained under Dr. Afsaneh Lavasanifar; both are co-inventors of Onco’s proprietary nanoparticle delivery technology. Days earlier, Onco reported producing approximately 952 grams of a key ONC010 precursor at kilogram scale through its collaboration with Dalton Pharma Services, setting the stage for the next phase of its manufacturing program. 

Building Toward the Clinic 

The history of cancer nanomedicine is a reminder that scientific promises and clinical reality do not always move in lockstep, and the field’s renewed momentum does not guarantee the success of any individual program. What it does suggest is that the questions now facing developers such as Onco-Innovations, surrounding delivery, formulation, scalability, and reproducibility, are increasingly becoming the right questions to ask.

As ONC010 advances toward first-in-human studies, the program reflects a broader shift underway across cancer nanomedicine, one focused not only on reducing drug toxicity but also on improving therapeutic performance. Whether that promise ultimately translates into clinical success remains to be seen, but the direction of the field is becoming increasingly clear.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• Beeline’s AI-enabled underwriting and customer acquisition tools are designed to reduce friction in mortgage approvals, particularly for gig-economy borrowers.
• Shares of Beeline Holdings, Inc. are set to join the Russell Microcap Index effective June 29, increasing visibility among institutional investors.
• The company’s first-quarter 2026 revenue more than doubled year over year to $2.7 million, while loan originations rose to $85.6 million.
• Management is targeting younger real estate investors alongside older homeowners seeking access to home equity without refinancing.
• The company continues investing in automation and adjacent software capabilities as it pursues a broader housing finance technology strategy.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to home ownership, was added as a member of the Russell Microcap Index, marking a notable milestone for the digital mortgage company as it attempts to scale its technology-driven lending platform during one of the most challenging housing finance environments in years.

The inclusion, effective June 29 following the annual Russell indexes reconstitution, places Beeline among a group of small-cap companies tracked by institutional investors and index-linked funds. According to FTSE Russell, approximately $12.2 trillion in assets are benchmarked against Russell US indexes. In a May 26 announcement, Chief Executive Officer Nick Liuzza said the company expects the addition to improve trading liquidity and broaden investor exposure to the business (https://ibn.fm/DeBYM).

Beeline has spent the last several years positioning itself as a technology-focused alternative to traditional mortgage originators. Through its subsidiary, Beeline Loans Inc., the company offers conventional mortgages alongside non-qualified mortgage products tailored to borrowers who may not fit standard underwriting models. The company’s strategy increasingly centers on automation, artificial intelligence and digital self-service tools designed to reduce approval timelines and simplify the financing process. Beeline says its platform can close loans in roughly 14 to 21 days, materially below broader industry averages.

During first-quarter 2026, Beeline reported revenue of $2.7 million, more than double the comparable period a year earlier. Loan originations increased to $85.6 million across 288 loans, up from $39.8 million and 128 loans in the prior-year quarter. The company’s recent operating results arrive at a time when many mortgage lenders continue grappling with elevated interest rates, muted refinancing demand and affordability pressures that have weighed heavily on housing activity nationwide.

Rather than chasing overall origination volume, management says the company is focusing on products with stronger economics. During Beeline’s quarterly earnings call, Liuzza emphasized that the company is prioritizing profitability and operational efficiency amid continued uncertainty surrounding inflation and capital markets. “We are leaning into the parts of the business that already work,” Liuzza said during the call. A major part of that strategy involves expanding Beeline’s presence in the Non-QM lending market, including debt-service coverage ratio loans and bank-statement products frequently used by self-employed borrowers and property investors.

The emphasis reflects broader demographic shifts reshaping the housing market. Younger borrowers, particularly millennials and members of Generation Z, continue facing significant barriers to homeownership. According to reporting by National Mortgage Professional, only 26.1% of Gen Z consumers and 54.9% of millennials owned homes in 2024, with mortgage qualification standards remaining a major obstacle for many applicants.

Beeline is attempting to address that gap through AI-assisted underwriting technology that can provide borrowers with rapid qualification assessments. The company says its digital tools can determine eligibility with roughly 90% certainty in as little as seven or eight minutes. The platform is also increasingly oriented toward younger consumers purchasing investment properties rather than only primary residences. Management argues that real estate investing may represent a more accessible path to wealth creation for borrowers navigating affordability constraints in traditional housing markets.

Chief Operating Officer Jess Kennedy said Beeline’s internally developed AI systems are helping improve conversion rates and operational efficiency. The company’s chatbot, known as Bob, has reportedly increased lead-to-lock conversion rates by approximately 8% when interacting with prospective borrowers online. Meanwhile, Beeline’s self-service mortgage workflow produced a 131% increase in application-to-lock pull-through during early deployment phases, according to company disclosures.

At the same time, Beeline is also targeting older homeowners through a separate equity-access platform called BeelineEquity. The product is designed to help homeowners monetize accumulated home equity without refinancing existing low-interest mortgages, an increasingly relevant issue in a higher-rate environment where many homeowners remain reluctant to replace mortgages originated during the ultra-low-rate period of 2020 and 2021.

Unlike conventional mortgage lending, BeelineEquity operates primarily as a fee-based business. The company says the product generates approximately 3.5% of transaction value in fees while also producing ancillary title revenue averaging around $1,500 per transaction. Management has emphasized that the structure carries no balance-sheet lending exposure.

Beeline also continues investing in adjacent software and automation capabilities. The company maintains a minority stake in MagicBlocks, an AI-focused sales platform supporting portions of Beeline’s internal infrastructure. During the latest earnings call, management disclosed that the software platform recently onboarded several major lenders, including one top-10 institution.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• Greenland Mines’ flagship Skaergaard Project hosts an NI 43-101 Mineral Resource estimate containing 11.4 million ounces PdEq in the Indicated category and 14.1 million ounces PdEq in the Inferred category.
• The pending acquisition of the Sarfartoq Project would add an advanced rare earth asset with a historical resource estimate, extensive drilling history and exposure to magnet rare earth elements including neodymium and praseodymium.
• The company’s relationship with Neo Performance Materials includes an offtake arrangement covering up to 60% of future Sarfartoq production, subject to completion of the acquisition and future project development.
• Greenland Mines is pursuing a North Atlantic critical minerals strategy that includes resource development in Greenland and potential downstream processing and logistics initiatives in Iceland.
• Greenland Mines’ strategic investment in AnorTech provides exposure to sustainable alumina, high purity alumina and related midstream processing opportunities that complement the company’s broader critical minerals strategy.

Greenland Mines (NASDAQ: GRML) is focused on the exploration and development of mineral assets in Greenland. Through its mining division, the company is advancing the Skaergaard Project in southeast Greenland while also pursuing the acquisition of the Sarfartoq rare earth project in southwest Greenland. Together, these assets provide exposure to precious metals, critical metals and rare earth elements within a jurisdiction that has attracted growing interest as governments and industries seek to diversify strategic mineral supply chains.

The company’s strategy centers on building a North Atlantic critical minerals platform that links resource development in Greenland with downstream processing, logistics infrastructure and industrial markets in Europe and North America. In June 2026, Greenland Mines expanded that strategy through a strategic investment in AnorTech Inc., providing exposure to sustainable alumina, high purity alumina and related industrial materials opportunities in Greenland. In addition to advancing its mineral assets, Greenland Mines has established relationships and initiatives designed to support future project development, including environmental studies, metallurgical work, infrastructure planning and downstream processing opportunities.

Greenland Mines also maintains a biotechnology division focused on developing therapies for neurodegenerative and age-related disorders. Supported by an experienced team spanning mining, geology, biotechnology and capital markets, the company is pursuing opportunities across both natural resources and life sciences.

The company is headquartered in Charlotte, North Carolina.

Mining

Greenland Mines’ mining division is centered on advancing the Skaergaard Project while pursuing the acquisition and development of the Sarfartoq rare earth project. The company has also made a strategic investment in AnorTech Inc., a Greenland-focused resource and technology company advancing sustainable alumina and high purity alumina opportunities. Together, these initiatives form the foundation of Greenland Mines’ North Atlantic critical minerals strategy.

Skaergaard Project

The Skaergaard Project is Greenland Mines’ flagship mineral asset located in southeast Greenland. The project hosts a stratiform palladium-gold-platinum deposit within the Skaergaard Intrusion and, according to the project’s NI 43-101 Technical Report effective Nov. 22, 2022, contains an Indicated Mineral Resource of 11.4 million ounces palladium equivalent (“PdEq”) within 159 million tonnes grading 2.23 g/t PdEq and an Inferred Mineral Resource of 14.1 million ounces PdEq within 205 million tonnes grading 2.14 g/t PdEq. Greenland Mines reports that approximately $30 million has been invested in the project since the 1990s, including approximately 45,000 meters of diamond drilling and channel sampling.

Greenland Mines controls three mineral exploration licenses covering approximately 877 square kilometers at Skaergaard and is advancing environmental, metallurgical and technical studies to support future development. The company has stated plans to pursue additional drilling, resource expansion and evaluation of potential critical-metal byproducts while also exploring downstream processing opportunities through initiatives in Iceland, including agreements related to the Helguvík industrial area that support its broader North Atlantic critical minerals strategy.

Sarfartoq Project

In May 2026, Greenland Mines entered into a definitive agreement to acquire Neo North Star Resources, Inc., owner of the Sarfartoq rare earth project in southwest Greenland. The project covers approximately 687 square kilometers and is centered on a large carbonatite complex that hosts rare earth mineralization. Its most advanced area, the ST1 Zone, contains a legacy NI 43-101 compliant Preliminary Economic Assessment-stage Mineral Resource estimate of 5.9 million tonnes of Indicated resources grading 1.8% total rare earth oxides (“TREO”), supported by extensive drilling, metallurgical testing, engineering studies and environmental work.

Sarfartoq is focused on magnet rare earth elements including neodymium and praseodymium, which are used in permanent magnets for electric vehicles, wind turbines, defense systems and other advanced technologies. Greenland Mines has highlighted the project’s infrastructure advantages, ongoing environmental studies and development potential, while an associated agreement with Neo Performance Materials provides offtake rights covering up to 60% of future production following completion of the acquisition.

Biotech

In addition to its mining activities, Greenland Mines operates a biotechnology division that includes KLTO-202, a gene therapy candidate with a primary indication for amyotrophic lateral sclerosis (“ALS”). The division is focused on developing biologic, cell and gene therapies targeting neurodegenerative and age-related disorders and is pursuing opportunities to advance and expand its therapeutic portfolio.

Market Opportunity

Rare earth elements and platinum group metals play important roles across industrial, energy, transportation and defense markets. Neodymium and praseodymium are key components in permanent magnets used in electric vehicles, wind turbines, robotics and high-efficiency motors, while palladium and platinum support a range of industrial and technology-related applications. As governments and manufacturers seek to strengthen access to strategic materials, critical minerals have become an increasing focus of industrial development and supply-chain planning.

Global demand for rare earth elements is projected to increase from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035, according to McKinsey & Company. The global rare earth elements market, valued at approximately $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030, according to Grand View Research. These trends are being driven by growing demand from electrification, renewable energy and advanced manufacturing industries.

China currently controls a significant portion of global rare earth mining and processing capacity, contributing to efforts across North America and Europe to establish alternative critical minerals supply chains. Through the Skaergaard Project and the pending acquisition of the Sarfartoq Project, Greenland Mines is building exposure to platinum group metals and magnet rare earth elements while advancing its strategy to support a North Atlantic critical minerals corridor linking Greenlandic resources with downstream processing, logistics infrastructure and industrial markets.

Leadership Team

Dr. Joseph Sinkule, Founder, Chief Executive Officer, Director and Chairman of the Board, has more than 40 years of experience in drug, biologic and medical-device research, development and commercialization. He has successfully managed multiple products through FDA approval and commercialization, founded numerous ventures and led financing, development and operational activities across pharmaceutical and biotechnology organizations. He also serves on corporate boards and advises investment firms and life sciences companies.

Jeffrey LeBlanc, Chief Financial Officer, brings more than two decades of experience in financial management, investing, advisory services and entrepreneurship. He is the co-founder of Winvest Acquisition Corp. and previously founded Out of Print, which was acquired by Penguin Random House in 2017. His prior experience includes investment roles at Greenlight Capital and GE Capital, as well as consulting work at McKinsey & Company. He holds an MBA from Harvard Business School and a Bachelor of Science in Chemical Engineering from MIT.

Dr. Bo Møller Stensgaard, President, has more than 20 years of experience in mineral exploration and natural resource development across Europe and the Arctic. A geologist with a PhD in economic geology, he previously served as a Senior Research Scientist at the Geological Survey of Denmark and Greenland and has led both public and private resource companies. His experience includes project advancement, permitting, environmental and social impact assessments, stakeholder engagement, investor relations and strategic advisory work related to European raw materials policy and funding.

For more information, visit the company’s website at https://greenlandmines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, recently received the delivery of a propane-fired tilting furnace at its Montauban Project to support on-site melting and casting of gold and silver into doré bars
• The furnace will form part of the company’s planned circuit for recovering precious metals from permitted tailings material and is a crucial milestone as the company moves to operationalize the facility
• ESGold has received – and continues to receive – infrastructure and equipment since April and continues to engage in activities that prepare the site for commissioning

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, recently took delivery of a propane-fired tilting furnace at its Montauban Gold-Silver Project in Quebec. The furnace, which features a hydraulic tilting system, supporting crucibles, and thermocouple temperature monitoring, can safely hold and melt up to 150 kilograms of metal and handle temperatures up to 1300°C (https://ibn.fm/MKcGT).

The furnace will form part of ESGold’s specialized equipment for on-site melting and casting of gold and silver into doré bars once the site is operational. The company intends to use the furnace in connection with its planned precious metal recovery circuit, which includes the Merrill-Crowe process, a technique for separating or recovering gold and silver from cyanide-based solutions or permitted tailings material.

“The delivery of this furnace is another practical and visible milestone in our transition from construction toward operations at Montauban,” commented Gordon Robb, CEO of ESGold. “This unit is part of the infrastructure required to move mineral recovery to doré production, and it reflects the steady progress being made across the project,” he added.

The furnace delivery marks another significant milestone as the company continues to advance the Montauban property toward commissioning and production. In addition to the furnace, the company has also received the Humphrey spirals and shaker tables, which collectively form part of Montauban’s gravity recovery circuit. The arrival of these major components at Montauban, Robb stated, allows investors to see “the processing infrastructure continuing to come together as we advance toward commissioning.” According to Robb, the continued delivery of the processing infrastructure, as well as advancements in site preparations, enable the company to build the “operational foundation required to bring Montauban into its next stage.”

ESGold is currently installing and integrating key processing equipment, developing the on-site precious metals handling infrastructure, and preparing the gold room and other supporting operational systems. In addition, the company is advancing, on a continued basis, its Montauban exploration model, which, according to the announcement, includes “ongoing integration of geological, geophysical, and historical datasets to support future exploration targets across the district.”

Covering approximately 244 square kilometers and home to 485 claims, the Montauban Project is being advanced to recover gold, silver, and mica from fully permitted historic mine tailings in the near term, with the company intending to commence gold and silver operations this year. In addition, ESGold is advancing district-scale exploration potential across the surrounding Montauban mining camp to feed its long-term strategy. The company is fully funded to commission the gold and silver operations and has completed the construction of a mill capable of processing up to 1,000 tons of precious metal per day (https://ibn.fm/XHQRh).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs.
• By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs.
• Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment.

The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.

This shift is helping fuel rapid growth in the nanomedicine and advanced drug-delivery sector, which is projected to reach approximately $410 billion by 2030. Rather than starting from scratch, nanomedicine seeks to enhance the performance of proven therapeutic compounds by improving their stability, targeting capabilities and overall effectiveness.

The opportunity is particularly compelling in oncology. Many cancer therapies are administered orally, a route that can present several challenges including poor bioavailability, inconsistent pharmacokinetics, limited tumor penetration and the potential for treatment resistance. Even highly effective compounds can see their therapeutic potential constrained by these delivery limitations.

Nanotechnology-based delivery systems are designed to overcome many of these obstacles. By improving how drugs are absorbed, distributed and delivered to tumor sites, researchers hope to increase efficacy while reducing unwanted side effects and treatment variability.

One company pursuing this strategy is Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on developing novel oncology solutions. The company’s proprietary Deciparticle(TM) platform utilizes nanoparticle engineering to reformulate hydrophobic drugs into intravenously administered nanoparticle therapies designed to improve delivery performance.

A key example is Sapu003, Oncotelic’s intravenous nanoparticle formulation of Everolimus, a widely used oncology drug. According to the company, the reformulation is designed to achieve near-complete bioavailability while improving tumor targeting and reducing toxicity. Oncotelic believes these improvements may help shift treatment outcomes beyond simply slowing tumor growth and toward more effective cancer cell destruction.

The potential implications extend beyond clinical performance. Successfully enhancing the delivery of existing drugs may create opportunities to extend product utility, improve patient outcomes and generate additional commercial value from compounds that have already demonstrated therapeutic relevance.

As interest in precision medicine and targeted oncology continues to grow, drug delivery technologies are increasingly being viewed as more than supporting tools. Instead, they are emerging as a critical layer of innovation that may help unlock the next generation of value creation in cancer therapeutics. For companies like Oncotelic Therapeutics, the ability to optimize how drugs reach and interact with tumors could prove just as important as discovering entirely new compounds.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• GLND is advancing exploration at the Jameson Project, one of Greenland’s most prospective yet historically underexplored resource regions
• The company is focused on unlocking economic opportunities that could support job creation, infrastructure development, and long-term revenue generation
• These developments align with a broader vision: empowering Greenland’s path toward greater economic independence through responsible resource development

Greenland Energy (NASDAQ: GLND) is positioning itself at the intersection of one of the Arctic’s most compelling economic opportunities. Through the company’s Jameson Project in East Greenland, it is pursuing resource exploration in an area that has long attracted geological interest but has seen only limited development. As Greenland seeks to improve its economic future and cut down dependence on external financial support, projects like Jameson highlight the critical role responsible resource development can play in building long-term prosperity.

The company’s focus on the Jameson Basin highlights a broader opportunity emerging across Greenland. Despite having significant natural resource potential, much of the country’s resource base is still underexplored relative to other energy-producing regions globally. Advances in exploration technology, as well as growing demand for secure energy sources, are creating momentum for development across the Arctic.

Greenland Energy is pursuing this opportunity through a strategy focused on identifying and advancing high-potential resource assets. The Jameson Project is situated within a basin sharing geological characteristics with productive North Atlantic petroleum systems, making it a viable target for modern exploration efforts. As additional geological data is being gathered and analyzed, the project has the potential to further increase interest in Greenland’s resource sector. 

Greenland’s resource opportunity extends beyond exploration. Successful development can create a ripple effect throughout the economy, generating skilled employment, attracting infrastructure investment, supporting local businesses, and expanding government revenues. These advantages have become even more vital as policymakers and citizens keep discussing long-term economic self-sufficiency and the gradual reduction in dependence on Danish block grants.

The company operates at the nexus of economic growth, resource development, and national opportunity. Greenland Energy is a part of a broader movement targeted at responsibly unlocking Greenland’s natural advantages while supporting local participation and sustainable development objectives. As global energy markets keep prioritizing supply security, jurisdictions with untapped resources and stable regulatory environments are drawing increased attention from industry participants and investors.

These updates perfectly align with the company’s broader mission: the responsible unlocking of Greenland’s energy potential, supporting both local development and global energy security through science-driven exploration and innovation. By advancing exploration activities in one of Greenland’s most promising frontier basins, the company is working hard to create opportunities that extend beyond resource discovery to encompass employment, investment, and long-term economic development.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,”

“forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.

These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors”.

Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Date: August 27, 2026

Venue: Sonesta Philadelphia Rittenhouse Hotel, Philadelphia, PA

Professionals and executives from clinical, legal, regulatory, and operational sectors are invited to attend the 7th Clinical Trial Agreements Summit, to be held on Aug. 27-28, 2026, at the Sonesta Philadelphia Rittenhouse Hotel in Philadelphia, Pennsylvania.

The event is hosted by Dynamic Global Events (“DGE”), a world leader in curating b2b events for life science companies. The summit aims to guide stakeholders in navigating the complex landscape of clinical trial agreements (“CTAs”), as they adapt to new regulations, technologies, and best practices.

Why attend?

• Industry experts will explore practical strategies for addressing the challenges in clinical trial contracting, such as decentralized trial operations, global data transfer requirements, cybersecurity considerations, post-trial access planning, and inspection readiness.
• Gain practical guidance for negotiating budgetary constraints, protecting intellectual property and clinical data, and reducing risks related to indemnification and subject injury.
•  Attendees will also gain insights into regulatory developments and emerging trends that may affect future clinical research agreements
• The event is expected to attract professionals from clinical contracts, legal affairs, clinical operations, compliance, regulatory affairs, corporate counsel, clinical development, medical affairs, and related disciplines.
• Participants can utilize this platform to connect with industry experts, exchange ideas, and expand their professional networks through educational sessions and interactive discussions.

Some key topics of discussion among industry leaders will include negotiation strategies, intellectual property protection, clinical data considerations, and risk mitigation approaches. The summit aims to provide attendees with actionable knowledge that can help streamline agreement processes and support more efficient clinical trial activation.

To learn more, please visit https://ibn.fm/fGgEH.

• For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size.
• What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity.
• The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.

Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.

The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the disease. 

The economic burden is equally staggering. For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. In addition, productivity losses are estimated to increase by 54%, from $234 billion to $361 billion. For investors evaluating the size of the opportunity, that backdrop establishes a market driven not by discretionary healthcare spending but by a chronic, escalating, and unavoidable national health crisis.

What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect heart attack risk and coronary heart disease earlier and with high sensitivity. The company’s two flagship tests, Epi+Gen CHD and PrecisionCHD, were developed using the company’s proprietary AI-driven Multi-Omics Engine. These tests analyze a combination of DNA methylation biomarkers (epigenetic markers) and genetic markers, called single nucleotide polymorphisms (“SNPs”), from a blood sample. Artificial intelligence is then used to interpret these genetic and epigenetic signals and generate personalized insights related to heart attack risk and coronary heart disease detection.” 

Epi+Gen CHD assesses a patient’s three-year risk for a coronary heart disease event, including heart attacks. PrecisionCHD aids in the diagnosis and management of coronary heart disease. Both tests are noninvasive and require no fasting or radiation. They can also be performed in a doctor’s office or from an at-home sample collection kit ordered through a telemedicine platform, a meaningful advantage in terms of patient accessibility and clinician adoption. According to Cardio Diagnostics, PrecisionCHD has a sensitivity of better than 75% for both men and women.

Perhaps the most clinically significant aspect of the PrecisionCHD test is initial data supporting its ability to detect nonobstructive forms of coronary heart disease, specifically ischemia with no obstructive coronary arteries (“INOCA”) and myocardial infarction with no obstructive coronary arteries (“MINOCA”), which standard tools including angiograms typically can miss. 

Preliminary clinical data supporting this capability was presented at the American Heart Association Scientific Sessions in November 2025, where a University of Iowa collaboration study of 267 hospitalized acute coronary syndrome patients demonstrated that PrecisionCHD’s methylation indices could detect INOCA. For the millions of patients who present with symptoms but receive a clear angiogram, only to suffer subsequent cardiac events, this is the kind of breakthrough that the clinical community has been seeking.

The company’s recent commercial and regulatory milestones give additional shape to the investment thesis. In late 2024, Cardio Diagnostics received finalized CMS reimbursement rates of $854 for its clinical tests, along with dedicated CPT Proprietary Laboratory Analysis codes from the American Medical Association, both critical steps toward mainstream insurance coverage and broad clinical adoption. 

Cardio Diagnostics’ recent commercial and reimbursement milestones have helped strengthen its commercialization strategy. In December 2025, the company announced that the Centers for Medicare & Medicaid Services (“CMS”) finalized a gapfill reimbursement rate of $854 for both its Epi+Gen CHD and PrecisionCHD tests, effective for services provided on or after January 1, 2026. 

Earlier, the American Medical Association assigned dedicated CPT Proprietary Laboratory Analysis (“PLA”) codes to both tests: 0439U for Epi+Gen CHD and 0440U for PrecisionCHD. Those codes became effective in April 2024. Dedicated reimbursement codes and established CMS payment rates are important steps that can facilitate payer billing, reimbursement and broader clinical adoption.

In addition, the company expanded its provider network in October 2025, adding 15 new provider organizations across the United States. In January 2026, Cardio Diagnostics announced its first international expansion through a strategic agreement with Aimil Ltd. and Dr. Lal PathLabs to launch the PrecisionCHD test in India, a market where cardiovascular disease carries an enormous and growing burden. Dr. Lal PathLabs operates more than 290 clinical laboratories and a network of 300-plus MD pathologists, providing immediate infrastructure for meaningful scale.

Cardio Diagnostics has also established a multichannel commercialization strategy that extends beyond traditional clinical settings. The company is actively pursuing employer and benefits partnerships, and announced that it will exhibit at four national employee benefits conferences in June 2026, targeting employers, brokers, union trustees and plan administrators for whom cardiovascular disease represents one of the largest drivers of medical claims costs. Community-based programs further extend the company’s reach into patient populations that traditional clinical channels may not efficiently serve.

For investors evaluating the diagnostics landscape, Cardio Diagnostics occupies a position that is both scientifically grounded and commercially actionable: a proprietary, AI-driven platform with reimbursement milestones, growing provider adoption, growing evidence supporting the ability to detect what traditional tools miss, and a multi-channel strategy designed to reach patients through clinical, employer, and community pathways simultaneously. 

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• American Fusion has filed a new patent application covering innovations expected to be incorporated into future commercial versions of its Texatron(TM) Fusion Engine(TM) platform.
• Management believes the technologies disclosed in the filing could ultimately support hundreds of additional patent applications as the platform evolves, with a growing intellectual property portfolio focused on fusion energy generation, plasma control, system architecture, and energy-delivery technologies.
• Through its wholly owned subsidiary, Kepler Fusion Technologies, American Fusion(TM) is pursuing a modular approach to fusion energy deployment, targeting industrial and commercial customers through behind-the-meter energy deployments before broader grid-scale applications.
• The company is currently developing multiple Texatron(TM) Fusion Engine(TM) models, including 5-megawatt and 100-megawatt systems intended to support future commercialization efforts.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, recently announced another step in its commercialization strategy with the filing of a new patent application covering innovations expected to be incorporated into future commercial versions of its Texatron(TM) Fusion Engine(TM) platform. According to the company, the application covers architectural and operational innovations currently being evaluated for future generations of the Texatron(TM) Fusion Engine(TM) following completion of Version 9 testing (https://ibn.fm/57OcR).

The filing represents the latest addition to a growing intellectual property portfolio that management views as an important component of long-term commercialization efforts.

“Intellectual property development remains a core pillar of our long-term strategy,” Executive Chairman Brent Nelson said in the company announcement. Management believes the technologies described within the latest application could ultimately support approximately 300 additional patent filings as future generations of the platform are developed. While those future filings remain prospective, the statement highlights the company’s emphasis on building a substantial intellectual property framework alongside ongoing engineering development.

Intellectual property often plays an important role in company valuations and competitive positioning in the fusion sector. Unlike traditional energy technologies, many fusion approaches rely on highly specialized reactor designs, plasma control systems, energy-delivery mechanisms, and supporting infrastructure. As a result, companies frequently seek broad patent protection around core technologies as they progress from prototype systems toward commercial deployment.

American Fusion(TM) states that its current intellectual property program spans technologies associated with fusion energy generation, plasma generation and control, system architecture, energy-delivery systems, and related platform innovations.

The company’s broader strategy reflects a growing trend within the fusion industry, where developers are increasingly focusing not only on technical milestones but also on protecting future commercial opportunities.

American Fusion(TM) emerged following the previously announced merger with Kepler Fusion Technologies, bringing the Texatron(TM) Fusion Engine(TM) platform under a publicly traded corporate structure. The company describes the Texatron(TM) Fusion Engine(TM) as a modular, infrastructure-grade fusion platform intended for industrial, commercial, and grid-constrained applications.

While fusion remains under development across the industry, American Fusion(TM) has articulated a commercialization strategy focused on scalable deployment rather than large, centralized facilities.

According to management, the company is currently developing nine Texatron(TM) Fusion Engine(TM) models and is constructing both a 5-megawatt demonstration system and a 100-megawatt commercial-scale design. The 100-megawatt system occupies a central role in the company’s commercialization plans.

Management has indicated that the modular architecture allows capacity to be expanded through standardized deployment. In practical terms, ten 100-megawatt units would provide approximately one gigawatt of generation capacity, creating a framework that can potentially be scaled over time as customer demand grows.

Rather than initially focusing on large utility-scale grid integration, American Fusion(TM) plans to pursue behind-the-meter deployments. This strategy involves placing generating assets directly at customer facilities, enabling industrial operators, manufacturers, data centers, and other large electricity users to access power generation on-site. Behind-the-meter deployment has become an increasingly discussed concept across the broader energy sector as companies seek greater control over energy costs, reliability, and infrastructure planning.

The company’s emphasis on modular deployment comes at a time when electricity demand forecasts continue to rise, driven by electrification trends, artificial intelligence infrastructure, advanced manufacturing, and data center expansion. These trends have renewed investor interest in a range of emerging energy technologies, including advanced nuclear systems, energy storage, and fusion.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN